Filing Flows › Foghorn Therapeutics (FHTX) › R&D spending
Foghorn Therapeutics (FHTX) R&D spending by quarter
Foghorn Therapeutics' R&D spending was $18.5M in Q2 2026 (second quarter 2026), +1% from Q1 2026. Over the last 7 quarters it ranged from $18.3M (Q1 2026) to $22.0M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $18.5M | +1% | -15% |
| Q1 2026 | $18.3M | -17% | -16% |
| Q4 2025 | $22.0M | +10% | +7% |
| Q3 2025 | $20.0M | -8% | — |
| Q2 2025 | $21.8M | +0.8% | — |
| Q1 2025 | $21.6M | +5% | — |
| Q4 2024 | $20.5M | — | — |
Q2 2026 at a glance
Foghorn Therapeutics, Q2 2026: revenue $16.1M (+113% year over year), operating margin -54.8%, net loss $7.2M, operating cash flow −$17.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Foghorn Therapeutics' R&D spending?
Foghorn Therapeutics' R&D spending was $18.5M in Q2 2026 (second quarter 2026), +1% from Q1 2026.
How has Foghorn Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $18.3M (Q1 2026) to $22.0M (Q4 2025).